Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Here are some of the stories Wall Street is watching on Friday, Aug. 22. Stocks and cryptocurrencies surged after Fed Chair ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has completed a clinical study titled ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk has completed a study titled A ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...

Whether it’s a cook, a home health aide, or a direct support professional, domestic workers are critical for so many people ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...